$BIOCQ
Biocept Inc

2021 Q2 Form 10-Q Financial Statement

#000156459021044664 Filed on August 16, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2 2020 Q1
Revenue $12.05M $917.5K $1.450M
YoY Change 1213.08% -22.99% 41.57%
Cost Of Revenue $7.462M $2.520M $2.950M
YoY Change 196.1% -5.74% 13.49%
Gross Profit $4.585M -$1.600M -$1.500M
YoY Change -386.58% 7.96% -4.77%
Gross Profit Margin 38.06% -174.39% -103.45%
Selling, General & Admin $5.196M $3.240M $3.370M
YoY Change 60.36% -1.55% 10.25%
% of Gross Profit 113.31%
Research & Development $1.138M $1.590M $1.310M
YoY Change -28.45% 38.47% 7.09%
% of Gross Profit 24.81%
Depreciation & Amortization $341.1K $240.0K $240.0K
YoY Change 42.12% 4.87% 9.09%
% of Gross Profit 7.44%
Operating Expenses $6.333M $4.830M $3.370M
YoY Change 31.12% 8.8% -21.27%
Operating Profit -$1.748M -$6.430M -$6.183M
YoY Change -72.82% 8.59% 5.6%
Interest Expense $79.69K -$60.00K -$60.00K
YoY Change -232.82% -194.38% 0.0%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 -$2.159M
YoY Change -100.0%
Pretax Income -$1.827M -$6.490M -$8.340M
YoY Change -71.84% -16.97% 40.88%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.827M -$6.489M -$8.341M
YoY Change -71.84% -16.97% 40.98%
Net Earnings / Revenue -15.17% -707.3% -575.26%
Basic Earnings Per Share -$0.14 -$0.11
Diluted Earnings Per Share -$135.7K -$510.2K -$0.11
COMMON SHARES
Basic Shares Outstanding 13.46M
Diluted Shares Outstanding 13.46M 79.00M

Balance Sheet

Concept 2021 Q2 2020 Q2 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $19.45M $24.05M $21.49M
YoY Change -19.12% 91.02% 45.6%
Cash & Equivalents $19.45M $24.05M $21.49M
Short-Term Investments
Other Short-Term Assets $897.4K $850.0K $430.0K
YoY Change 5.57% 44.07% 59.26%
Inventory $3.016M $970.0K $920.0K
Prepaid Expenses
Receivables $12.60M $3.180M $3.420M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $35.96M $29.06M $26.26M
YoY Change 23.75% 81.72% 50.14%
LONG-TERM ASSETS
Property, Plant & Equipment $2.078M $3.960M $3.550M
YoY Change -47.51% 224.83% -19.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $438.8K
YoY Change
Total Long-Term Assets $14.64M $3.960M $3.550M
YoY Change 269.76% 1.19% -19.35%
TOTAL ASSETS
Total Short-Term Assets $35.96M $29.06M $26.26M
Total Long-Term Assets $14.64M $3.960M $3.550M
Total Assets $50.60M $33.02M $29.81M
YoY Change 53.25% 65.89% 36.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.706M $1.930M $2.410M
YoY Change 195.64% -4.48% 6.64%
Accrued Expenses $2.411M $2.480M $2.850M
YoY Change -2.78% 66.35% -19.03%
Deferred Revenue
YoY Change
Short-Term Debt $416.5K $440.0K $60.00K
YoY Change -5.35% 69.23%
Long-Term Debt Due $1.068M $790.0K $720.0K
YoY Change 35.13% 23.44% 12.5%
Total Short-Term Liabilities $9.654M $5.630M $6.030M
YoY Change 71.48% -3.3% -6.22%
LONG-TERM LIABILITIES
Long-Term Debt $1.626M $1.300M $1.050M
YoY Change 25.07% 51.16% 8.25%
Other Long-Term Liabilities $9.971M $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $11.60M $1.300M $1.050M
YoY Change 792.08% 32.19% -27.7%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.654M $5.630M $6.030M
Total Long-Term Liabilities $11.60M $1.300M $1.050M
Total Liabilities $21.25M $6.930M $7.080M
YoY Change 206.66% 1.83% -10.15%
SHAREHOLDERS EQUITY
Retained Earnings -$262.8M
YoY Change
Common Stock $292.1M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $29.35M $26.08M $22.73M
YoY Change
Total Liabilities & Shareholders Equity $50.60M $33.02M $29.81M
YoY Change 53.25% 65.89% 36.18%

Cashflow Statement

Concept 2021 Q2 2020 Q2 2020 Q1
OPERATING ACTIVITIES
Net Income -$1.827M -$6.489M -$8.341M
YoY Change -71.84% -16.97% 40.98%
Depreciation, Depletion And Amortization $341.1K $240.0K $240.0K
YoY Change 42.12% 4.87% 9.09%
Cash From Operating Activities $1.971M -$6.690M -$5.279M
YoY Change -129.47% -0.45% 0.6%
INVESTING ACTIVITIES
Capital Expenditures -$121.9K -$20.00K $18.51K
YoY Change 509.25% -66.67% -43.74%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$121.9K -$20.00K -$18.51K
YoY Change 509.25% -66.67% -43.74%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.404M 9.270M 17.49M
YoY Change -63.28% 101.52% 5.23%
NET CHANGE
Cash From Operating Activities 1.971M -6.690M -5.279M
Cash From Investing Activities -121.9K -20.00K -18.51K
Cash From Financing Activities 3.404M 9.270M 17.49M
Net Change In Cash 5.253M 2.560M 12.19M
YoY Change 105.21% -217.43% 7.52%
FREE CASH FLOW
Cash From Operating Activities $1.971M -$6.690M -$5.279M
Capital Expenditures -$121.9K -$20.00K $18.51K
Free Cash Flow $2.093M -$6.670M -$5.297M
YoY Change -131.38% 0.15% 0.32%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Net
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsNet
316772
CY2021Q2 bioc Supplier Financings
SupplierFinancings
416471
CY2021Q2 us-gaap Cost Of Revenue
CostOfRevenue
7461819
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3250859
CY2021Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1944661
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1747787
CY2021Q2 us-gaap Interest Expense
InterestExpense
79692
us-gaap Interest Expense
InterestExpense
112342
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y4M9D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y1M17D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y1M17D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.631
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.701
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
2306708
CY2020Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
72608
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-6489303
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
23692422
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
460201
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
760
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
2599292
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
13794953
us-gaap Interest Expense
InterestExpense
144933
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
26771227
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
494330
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-1827479
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
29351823
us-gaap Profit Loss
ProfitLoss
-14830641
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
47451586
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1459550
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
2111
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
287217949
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14310606
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
292105446
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2111
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-263526867
CY2020Q4 us-gaap Liabilities
Liabilities
23759164
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
2111
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-262755054
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2111
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
23692422
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14310606
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13397041
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
29351823
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13397041
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1340
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q2 us-gaap Liabilities
Liabilities
21251457
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9805361
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
1431
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12047166
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50603280
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1137614
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
22730105
bioc Deemed Dividend Related To Warrants Down Round Provision
DeemedDividendRelatedToWarrantsDownRoundProvision
2774
CY2020Q1 bioc Adjustment To Additional Paid In Capital Warrant Inducement Expense
AdjustmentToAdditionalPaidInCapitalWarrantInducementExpense
2102109
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-8341338
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
194236
CY2020Q1 bioc Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
265000
CY2020Q2 bioc Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
monthly
CY2020Q2 bioc Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
2025-06
bioc Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
21330
us-gaap Profit Loss
ProfitLoss
771813
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
26757686
us-gaap Depreciation And Amortization
DepreciationAndAmortization
477396
us-gaap Depreciation And Amortization
DepreciationAndAmortization
711099
bioc Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
-96962
bioc Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
720607
bioc Increase Decrease In Inventory Reserve
IncreaseDecreaseInInventoryReserve
-54202
bioc Increase Decrease In Inventory Reserve
IncreaseDecreaseInInventoryReserve
59901
us-gaap Share Based Compensation
ShareBasedCompensation
337200
us-gaap Share Based Compensation
ShareBasedCompensation
954531
us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
2102109
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-459
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-3941
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-347861
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1549217
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
259900
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1026817
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-11232
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1876097
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4916
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1921583
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-108406
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-754730
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11970366
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2811406
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
35457
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
831852
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35457
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-831852
bioc Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
24236358
bioc Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
3913745
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2379316
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
18552
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
760
bioc Proceeds From Exercise Of Overallotment Warrants
ProceedsFromExerciseOfOverallotmentWarrants
659958
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
311576
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
623895
us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
206370
us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
205469
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3103693
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
14751863
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5083247
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9301406
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14367942
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24053269
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19451189
us-gaap Interest Paid Net
InterestPaidNet
112342
us-gaap Interest Paid Net
InterestPaidNet
144933
bioc Financial Guarantee Insurance Contracts Premium Payable
FinancialGuaranteeInsuranceContractsPremiumPayable
567000
bioc Financial Guarantee Insurance Contracts Premium Payable
FinancialGuaranteeInsuranceContractsPremiumPayable
622000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
703000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
894000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
57000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
88000
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On September 3, 2020, pursuant to the approval of the Company’s board of directors, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s outstanding common stock using a ratio of one-for-ten.
CY2020Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
917471
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12047166
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2364020
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
29803356
CY2021Q2 bioc Additional Reserves Related To Aged Account Receivable
AdditionalReservesRelatedToAgedAccountReceivable
1100000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
917471
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12047166
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2364020
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
29803356
CY2020Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
4500000
CY2021Q2 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
4300000
CY2021Q2 us-gaap Cash
Cash
19500000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-262800000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-17800000
us-gaap Net Income Loss
NetIncomeLoss
771813
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19800000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2800000
CY2021Q2 bioc Aggregate Net Interest Bearing Indebtedness
AggregateNetInterestBearingIndebtedness
3100000
CY2021Q2 bioc Aggregate Net Interest Bearing Indebtedness Due Within One Year
AggregateNetInterestBearingIndebtednessDueWithinOneYear
1500000
CY2021Q2 bioc Other Non Interest Bearing Current Liabilities
OtherNonInterestBearingCurrentLiabilities
2400000
CY2021Q2 bioc Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
3900000
CY2021Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
908044
CY2020Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1900000
bioc Warrant Inducement Expense
WarrantInducementExpense
2100000
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2300000
CY2020Q1 us-gaap Share Price
SharePrice
4.00
CY2020Q1 bioc Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
8600000
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1600000
CY2020Q1 us-gaap Share Price
SharePrice
4.10
CY2020Q1 bioc Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
6100000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
10024787
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
107672
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
139992
us-gaap Operating Lease Payments
OperatingLeasePayments
732973
us-gaap Operating Lease Payments
OperatingLeasePayments
106272
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1078704
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
318410
CY2020Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2230000
CY2020Q2 us-gaap Share Price
SharePrice
4.60
CY2020Q2 bioc Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
9600000
CY2020Q1 bioc Estimated Grant Date Fair Value Of Warrants
EstimatedGrantDateFairValueOfWarrants
2.80
CY2020Q1 bioc Unregistered Warrants Issued Grant Date Fair Value
UnregisteredWarrantsIssuedGrantDateFairValue
1900000
CY2019Q1 bioc Adjusted Exercise Price Of Warrants
AdjustedExercisePriceOfWarrants
12.00
CY2019Q1 bioc Adjusted Exercise Price Of Warrants
AdjustedExercisePriceOfWarrants
12.50
CY2020Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.495
CY2019Q1 bioc Estimated Fair Value Of Warrants
EstimatedFairValueOfWarrants
2.70
CY2019Q1 bioc Estimated Fair Value Of Warrants
EstimatedFairValueOfWarrants
2.70
CY2019Q1 bioc Estimated Fair Value Of Warrants Increased
EstimatedFairValueOfWarrantsIncreased
2.90
CY2019Q1 bioc Estimated Fair Value Of Warrants Increased
EstimatedFairValueOfWarrantsIncreased
3.00
CY2019Q1 bioc Class Of Warrants Or Rights Eligible For Price Modification
ClassOfWarrantsOrRightsEligibleForPriceModification
216725
CY2019Q1 bioc Class Of Warrants Or Rights Eligible For Price Modification
ClassOfWarrantsOrRightsEligibleForPriceModification
476000
CY2019Q1 bioc Warrant Inducement Expense
WarrantInducementExpense
60000
CY2019Q1 bioc Warrant Inducement Expense
WarrantInducementExpense
130000
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1235620
CY2021Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
2328339
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
691126
CY2021Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
675072
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2878
CY2021Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
12931
CY2020Q4 us-gaap Inventory Gross
InventoryGross
1929624
CY2021Q2 us-gaap Inventory Gross
InventoryGross
3016342
CY2020Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
2974320
CY2021Q2 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
3035532
CY2020Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
156987
CY2021Q2 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
156987
CY2020Q4 bioc Computer Equipment And Software Gross
ComputerEquipmentAndSoftwareGross
2428211
CY2021Q2 bioc Computer Equipment And Software Gross
ComputerEquipmentAndSoftwareGross
2675926
CY2020Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
570173
CY2021Q2 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
485360
CY2020Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
761221
CY2021Q2 us-gaap Construction In Progress Gross
ConstructionInProgressGross
17396
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6890912
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6371201
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4573296
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4292737
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2317616
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2078464
CY2020Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
452118
CY2021Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
467451
CY2020Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
868557
CY2021Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
945572
CY2020Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1022421
CY2021Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
619031
CY2020Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
456526
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1810837
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2359348
CY2020Q2 bioc Finance Leases Sales Tax And Maintenance Obligations Expense
FinanceLeasesSalesTaxAndMaintenanceObligationsExpense
30000
CY2021Q2 bioc Finance Leases Sales Tax And Maintenance Obligations Expense
FinanceLeasesSalesTaxAndMaintenanceObligationsExpense
43000
bioc Finance Leases Sales Tax And Maintenance Obligations Expense
FinanceLeasesSalesTaxAndMaintenanceObligationsExpense
62000
bioc Finance Leases Sales Tax And Maintenance Obligations Expense
FinanceLeasesSalesTaxAndMaintenanceObligationsExpense
87000
CY2021Q2 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
220139
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
366047
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
158746
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3165669
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2410939
CY2020Q1 bioc Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
197000
CY2020Q1 bioc Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
monthly
CY2020Q1 bioc Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
4532
CY2020Q1 bioc Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
2025-01
CY2020Q1 bioc Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
11000
CY2020Q1 bioc Finance Lease Transaction Number Of Installment Payments
FinanceLeaseTransactionNumberOfInstallmentPayments
48
CY2020Q1 bioc Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
monthly
CY2020Q1 bioc Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
288
CY2020Q1 bioc Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
14000
CY2020Q1 bioc Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
2024-02
CY2020Q2 bioc Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
161000
CY2020Q2 bioc Finance Lease Transaction Number Of Installment Payments
FinanceLeaseTransactionNumberOfInstallmentPayments
60
CY2020Q2 bioc Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
3337
CY2020Q2 bioc Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
185000
CY2020Q2 bioc Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
2025-03
CY2020Q2 bioc Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
334000
CY2020Q2 bioc Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
monthly
CY2020Q2 bioc Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
8966
CY2020Q2 bioc Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
469000
bioc Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
894000
bioc Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
monthly
CY2021Q2 bioc Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
1064000
bioc Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
2026-03
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9776349
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9275168
CY2020Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
2337709
CY2021Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
2850277
CY2020Q4 bioc Operating And Finance Lease Right Of Use Assets
OperatingAndFinanceLeaseRightOfUseAssets
12114058
CY2021Q2 bioc Operating And Finance Lease Right Of Use Assets
OperatingAndFinanceLeaseRightOfUseAssets
12125445
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
53741
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
963726
CY2021Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1067516
CY2020Q4 bioc Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
963726
CY2021Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1625939
CY2020Q4 bioc Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
11264911
CY2021Q2 bioc Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
11596985
CY2021Q2 bioc Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
1121257
CY2020Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
129576
CY2021Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
209181
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
274106
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
381506
CY2020Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
50975
CY2021Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
74751
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
107672
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
139992
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
318005
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
414384
us-gaap Operating Lease Cost
OperatingLeaseCost
636010
us-gaap Operating Lease Cost
OperatingLeaseCost
829186
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9805361
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9971046
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1459550
CY2020Q2 bioc Operating And Finance Lease Cost
OperatingAndFinanceLeaseCost
498556
CY2021Q2 bioc Operating And Finance Lease Cost
OperatingAndFinanceLeaseCost
698316
bioc Operating And Finance Lease Cost
OperatingAndFinanceLeaseCost
1017788
bioc Operating And Finance Lease Cost
OperatingAndFinanceLeaseCost
1350684
CY2021Q2 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
600649
CY2021Q2 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Remainder Of Fiscal Year
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsRemainderOfFiscalYear
57777
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
442454
CY2021Q2 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
1020965
CY2021Q2 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Due Next Twelve Months
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDueNextTwelveMonths
101578
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1586210
CY2021Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
873830
CY2021Q2 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Due In Two Years
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDueInTwoYears
85427
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1629025
CY2021Q2 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
464328
CY2021Q2 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Due In Three Years
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDueInThreeYears
55806
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1671841
CY2021Q2 bioc Finance Lease Liability Payments Due After Year Three
FinanceLeaseLiabilityPaymentsDueAfterYearThree
209372
CY2021Q2 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Due Thereafter
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDueThereafter
16184
CY2021Q2 bioc Lessee Operating Lease Liability Payments Due After Year Three
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree
11995434
CY2021Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
3169144
CY2021Q2 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Due
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDue
316772
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
17324964
CY2021Q2 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
475689
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7300177
CY2021Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
2693455
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
311576
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
623895
CY2021Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y1M9D
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y11M1D
CY2021Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.1766
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.120
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
894000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.64
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.17
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
194
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.91
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
72633
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
13.95
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1324287
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.90
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1298653
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
10.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M28D
CY2020Q4 bioc Common Stock Warrants Outstanding Intrinsic Value
CommonStockWarrantsOutstandingIntrinsicValue
243000
CY2021Q2 bioc Common Stock Warrants Outstanding Intrinsic Value
CommonStockWarrantsOutstandingIntrinsicValue
173000
bioc Number Of Warrants Included In Calculation Of Dilutive Weighted Average Shares
NumberOfWarrantsIncludedInCalculationOfDilutiveWeightedAverageShares
256461
bioc Number Of Options Included In Calculation Of Dilutive Weighted Average Shares
NumberOfOptionsIncludedInCalculationOfDilutiveWeightedAverageShares
582
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
215449
CY2021Q2 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Due
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDue
316772

Files In Submission

Name View Source Status
0001564590-21-044664-index-headers.html Edgar Link pending
0001564590-21-044664-index.html Edgar Link pending
0001564590-21-044664.txt Edgar Link pending
0001564590-21-044664-xbrl.zip Edgar Link pending
bioc-10q_20210630.htm Edgar Link pending
bioc-10q_20210630_htm.xml Edgar Link completed
bioc-20210630.xsd Edgar Link pending
bioc-20210630_cal.xml Edgar Link unprocessable
bioc-20210630_def.xml Edgar Link unprocessable
bioc-20210630_lab.xml Edgar Link unprocessable
bioc-20210630_pre.xml Edgar Link unprocessable
bioc-ex102_260.htm Edgar Link pending
bioc-ex311_8.htm Edgar Link pending
bioc-ex312_11.htm Edgar Link pending
bioc-ex321_12.htm Edgar Link pending
bioc-ex322_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending